RXRX
RECURSION PHARMACEUTICALS, INC. · Healthcare · Market cap $1.9B
Insiders sold $644K net in the last 90 days ·3 sellers, 0 buyers· 5 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 7, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.2M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Oct 7, 2026
Borgeson Blake
RECURSION PHARMACEUTICALS, INC. (RXRX) has 71 SEC Form 4 filings (105 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
Inside the rolling window, 6 insiders at RECURSION PHARMACEUTICALS, INC. reported no open-market purchases and 36 open-market sales totaling $8.2M. The most active filer is Director Gibson Christopher with 15 filings. Insiders have net sold $1.7M over the trailing 6 months. The most recent open-market filing is a sale of 50,000 shares by Director Borgeson Blake, dated Oct 6, 2026, worth $242K.
- Industry:Biotechnology
- CEO:Najat Khan
- Employees:600
- HQ:Salt Lake City, UT, US
- IPO:2021-04-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 50,000 | $242K | Oct 7 | -14.8% | SEC ↗ | |
| Director | Sale | 25,000 | $125K | Oct 7 | -14.8% | SEC ↗ | |
Khan NajatFirst in 3 months | CEO and President | Sale | 22,408 | $79K | Sep 10 | +15.2% | SEC ↗ |
| Director | Sale | 30,000 | $100K | Sep 2 | +7.7% | SEC ↗ | |
| Director | Sale | 30,000 | $98K | Aug 6 | +14.5% | SEC ↗ | |
| Director | Sale | 40,000 | $159K | Jul 9 | -3.2% | SEC ↗ | |
| Director | Sale | 3,963 | $13K | Jun 22 | +14.5% | SEC ↗ | |
| Director | Sale | 40,000 | $145K | Jun 5 | +9.8% | SEC ↗ | |
| CEO and President | Sale | 23,588 | $84K | Jun 5 | +9.8% | SEC ↗ | |
| Director | Sale | 30,000 | $110K | Jun 4 | -4.2% | SEC ↗ | |
Bumpus NamandjeFirst filing | Director | Sale | 4,386 | $16K | Jun 4 | — | SEC ↗ |
| Director | Sale | 40,000 | $123K | May 27 | — | SEC ↗ | |
| Director | Sale | 40,000 | $135K | May 8 | — | SEC ↗ | |
| Director | Sale | 30,000 | $106K | May 7 | — | SEC ↗ | |
| Director | Sale | 40,000 | $144K | Apr 24 | — | SEC ↗ | |
| Director | Sale | 40,000 | $124K | Apr 8 | — | SEC ↗ | |
| Director | Sale | 30,000 | $93K | Apr 8 | — | SEC ↗ | |
| Director | Sale | 40,000 | $130K | Mar 25 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 7,956 | $27K | Mar 18 | — | SEC ↗ | |
| CEO and President | Sale | 28,298 | $95K | Mar 11 | — | SEC ↗ | |
| Director | Sale | 170,000 | $588K | Mar 4 | — | SEC ↗ | |
| Director | Sale | 40,000 | $138K | Feb 19 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 13,426 | $41K | Feb 19 | — | SEC ↗ | |
| Director | Sale | 40,000 | $165K | Feb 6 | — | SEC ↗ | |
| Director | Sale | 220,000 | $924K | Feb 6 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does RXRX have?
RECURSION PHARMACEUTICALS, INC. (RXRX) has 71 SEC Form 4 filings (105 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
When was the most recent SEC Form 4 filing for RXRX?
The most recent Form 4 filing for RXRX on Tracefour is dated Oct 7, 2026.
Who is the most active insider at RXRX?
The most active SEC Form 4 filer at RXRX in the rolling window is Director Gibson Christopher, with 15 filings.
What is the net insider flow at RXRX over the last 6 months?
Over the trailing 180 days, insiders at RXRX have net sold $1.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RXRX in the current window?
Inside the rolling window, insiders at RXRX bought $0 and sold $8.2M based on SEC Form 4 filings.
Can I get alerts for RXRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at RECURSION PHARMACEUTICALS, INC. (RXRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
RECURSION PHARMACEUTICALS, INC. is in the Healthcare sector.